MCID: RSP002
MIFTS: 58

Respiratory Syncytial Virus Infectious Disease

Categories: Infectious diseases

Aliases & Classifications for Respiratory Syncytial Virus Infectious Disease

MalaCards integrated aliases for Respiratory Syncytial Virus Infectious Disease:

Name: Respiratory Syncytial Virus Infectious Disease 12
Respiratory Syncytial Virus Infections 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1273
MeSH 44 D018357
NCIt 50 C3354
SNOMED-CT 68 186750007 55735004
UMLS 73 C0035235

Summaries for Respiratory Syncytial Virus Infectious Disease

CDC : 3 Respiratory syncytial (sin-SISH-uhl) virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. It is also a significant cause of respiratory illness in older adults.

MalaCards based summary : Respiratory Syncytial Virus Infectious Disease, also known as respiratory syncytial virus infections, is related to pulmonary eosinophilia and allergic asthma, and has symptoms including runny nose, fever and cough. An important gene associated with Respiratory Syncytial Virus Infectious Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs RespiGam and Synagis have been mentioned in the context of this disorder. Affiliated tissues include upper respiratory tract or, lung and heart, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A viral infectious disease that results in infection located in upper respiratory tract or located in lower respiratory tract, has material basis in Human respiratory syncytial virus, which is transmitted by droplet spread of nasal secretions from an infected person while coughing or sneezing, or transmitted by contaminated fomites. The infection has symptom runny nose, has symptom fever, has symptom cough, has symptom wheezing, and has symptom respiratory distress.

Related Diseases for Respiratory Syncytial Virus Infectious Disease

Diseases related to Respiratory Syncytial Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 pulmonary eosinophilia 30.6 CCL5 IL13 IL5
2 allergic asthma 30.1 CCL5 IL13 IL5
3 asthma 29.6 CCL3 CCL5 IL13 IL5
4 parainfluenza virus type 3 29.5 IFNB1 NEU1
5 bronchiolitis 29.4 CCL3 CCL5 IL13 IL5
6 pneumonia 28.6 CCL3 CCL5 IL13 IL5 SFTPB
7 lung disease 28.4 CCL3 CCL5 IL13 IL5 SFTPB
8 cytokine deficiency 10.6 IL13 IL5
9 chronic eosinophilic pneumonia 10.6 CCL5 IL5
10 angioimmunoblastic lymphadenopathy with dysproteinemia 10.6 IL13 IL5
11 gastrointestinal allergy 10.6 CCL5 IL5
12 status asthmaticus 10.6 CCL5 IL5
13 inflammatory bowel disease 4 10.6 IL13 IL5
14 paragonimiasis 10.6 IL13 IL5
15 angiostrongyliasis 10.6 IL13 IL5
16 strongyloidiasis 10.6 IL13 IL5
17 kimura disease 10.6 CCL5 IL5
18 apple allergy 10.6 IL13 IL5
19 ascaris lumbricoides infection 10.6 IL13 IL5
20 folliculitis 10.6 CCL5 IL5
21 latex allergy 10.6 IL13 IL5
22 eosinophilic meningitis 10.6 IL13 IL5
23 african tick-bite fever 10.6 CCL5 IL13
24 intestinal schistosomiasis 10.6 IL13 IL5
25 urinary schistosomiasis 10.5 IL13 IL5
26 radiculopathy 10.5 CCL5 IL5
27 eosinophilic gastritis 10.5 IL13 IL5
28 chronic tic disorder 10.5 IL13 IL5
29 esophagitis, eosinophilic, 1 10.5 IL13 IL5
30 pollen allergy 10.5 IL13 IL5
31 yellow fever 10.5 CCL5 IL5
32 conjunctival disease 10.5 IL13 IL5
33 enterobiasis 10.5 IL13 IL5
34 necatoriasis 10.5 CCL3 IL5
35 esophageal disease 10.5 IL13 IL5
36 paranasal sinus disease 10.4 IL13 IL5
37 whiplash 10.4 CCL3 CCL5
38 allergic conjunctivitis 10.4 IL13 IL5
39 nasal cavity disease 10.4 IL13 IL5
40 nose disease 10.4 IL13 IL5
41 parasitic helminthiasis infectious disease 10.4 IL13 IL5
42 upper respiratory tract disease 10.4 IL13 IL5
43 stachybotrys chartarum 10.4 CCL3 CCL5
44 mast cell disease 10.4 IL13 IL5
45 leukocyte disease 10.3 IL13 IL5
46 chronic nk-cell lymphocytosis 10.3 CCL3 CCL5
47 orofacial granulomatosis 10.3 CCL3 CCL5
48 filariasis 10.3 CCL5 IL5
49 conjunctivitis 10.3 IL13 IL5
50 keratoconjunctivitis 10.2 IL13 IL5

Graphical network of the top 20 diseases related to Respiratory Syncytial Virus Infectious Disease:



Diseases related to Respiratory Syncytial Virus Infectious Disease

Symptoms & Phenotypes for Respiratory Syncytial Virus Infectious Disease

Symptoms:

12
  • runny nose
  • fever
  • cough
  • wheezing
  • respiratory distress

UMLS symptoms related to Respiratory Syncytial Virus Infectious Disease:


coughing, fever, pruritus, snoring

MGI Mouse Phenotypes related to Respiratory Syncytial Virus Infectious Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.43 CCL5 IFNB1 IL13 IL5 IRF1 NEU1
2 immune system MP:0005387 9.1 CCL5 IFNB1 IL13 IL5 IRF1 NEU1

Drugs & Therapeutics for Respiratory Syncytial Virus Infectious Disease

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
RespiGam 18 MedImmune January 1996
2
Synagis 18 PALIVIZUMAB MedImmune June 1998

Drugs for Respiratory Syncytial Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 1,Phase 2
2 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2
3 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4
Palivizumab Approved, Investigational Phase 2, Phase 3,Phase 3 188039-54-5
5
Ribavirin Approved Phase 3,Phase 2 36791-04-5 37542
6 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1
7 Antiviral Agents Phase 2, Phase 3,Phase 3,Phase 1
8 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
9 Immunoglobulin G Phase 3
10 Antimetabolites Phase 3,Phase 2
11 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
12 Calamus Nutraceutical Phase 3
13
Coal tar Approved Phase 2 8007-45-2
14
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
15
Azithromycin Approved Phase 2 83905-01-5 55185 447043
16
Budesonide Approved Phase 2 51333-22-3 63006 5281004
17
Montelukast Approved Phase 2 158966-92-8 5281040
18
Oseltamivir Approved Phase 2 204255-11-8, 196618-13-0 65028
19
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
20
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
21
Histidine Approved, Nutraceutical Phase 2 71-00-1 6274
22 tannic acid Approved, Nutraceutical Phase 2
23 Anti-Asthmatic Agents Phase 2
24 Respiratory System Agents Phase 2
25 Anti-Inflammatory Agents Phase 2
26 Antineoplastic Agents, Hormonal Phase 2
27 Antipyretics Phase 2
28 Budesonide, Formoterol Fumarate Drug Combination Phase 2
29 Formoterol Fumarate Phase 2
30 gamma-Globulins Phase 2
31 glucocorticoids Phase 2
32 Hormone Antagonists Phase 2
33 Hormones Phase 2
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
35 Immunoglobulins, Intravenous Phase 2
36 Leukotriene Antagonists Phase 2
37 Rho(D) Immune Globulin Phase 2
38
BCG vaccine Investigational Phase 1
39 Antibodies, Blocking Phase 1
40 Adjuvants, Immunologic Phase 1
41
Menthol Approved 2216-51-5 16666
42
Epinephrine Approved, Vet_approved Not Applicable 51-43-4 5816
43
Racepinephrine Approved Not Applicable 329-65-7 838
44
Nitric Oxide Approved 10102-43-9 145068 160954
45
Cocaine Approved, Illicit 50-36-2 5760 446220
46 Epinephryl borate Not Applicable
47 Antioxidants
48 Autonomic Agents
49 Bronchodilator Agents
50 Endothelium-Dependent Relaxing Factors

Interventional clinical trials:

(show top 50) (show all 137)
# Name Status NCT ID Phase Drugs
1 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4 RSV Polyclonal Immunoglobulin
2 Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™ Completed NCT00377611 Phase 4
3 Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children Completed NCT01006629 Phase 2, Phase 3
4 Study to Evaluate the Efficacy and Safety of REGN2222, for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants Completed NCT02325791 Phase 3 REGN2222;Placebo
5 Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions Completed NCT01466062 Phase 3 Palivizumab
6 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children Completed NCT00129766 Phase 3
7 Effect of Heliox on RSV Bronchiolitis Completed NCT03171142 Phase 3 Heliox;Air
8 A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus Completed NCT02968173 Phase 3 Palivizumab
9 Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation Completed NCT00016081 Phase 3 ribavirin
10 A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults Completed NCT02608502 Phase 3
11 A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization Active, not recruiting NCT02624947 Phase 3
12 Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients Terminated NCT00031473 Phase 3 Virazole (Ribavirin) Inhalation Solution
13 Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection Completed NCT02387606 Phase 2 Placebo;JNJ-53718678
14 Safety, Pharmacokinetics and Antiviral Activity of RV521 Against RSV Completed NCT03258502 Phase 2 RV521;Placebo
15 A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT Completed NCT00232635 Phase 2 A-60444
16 A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model Completed NCT02094365 Phase 2 ALS-008176;vehicle
17 Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus Completed NCT00496821 Phase 2 ALN-RSV01
18 A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study Completed NCT03382431 Phase 1, Phase 2 PC786;Placebo/vehicle
19 A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women Completed NCT02956837 Phase 2 Placebo (Formulation buffer S9b)
20 Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women Completed NCT02753413 Phase 2
21 A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus Completed NCT02673476 Phase 2 ALS-008176;Placebo
22 Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women Completed NCT02360475 Phase 2
23 RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. Completed NCT02247726 Phase 2 Saline Placebo (0.5mL injection);RSV F vaccine (0.5mL injection)
24 RSV F Dose-Ranging Study in Women Completed NCT01960686 Phase 2
25 Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) Completed NCT01756482 Phase 2 GS-5806;Placebo
26 Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Completed NCT01065935 Phase 2 ALN-RSV01;Normal Saline
27 Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Completed NCT00658086 Phase 2 ALN-RSV01;normal saline
28 Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524 Completed NCT00192478 Phase 1, Phase 2
29 Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract Completed NCT02254408 Phase 2 Presatovir;Placebo
30 Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract Completed NCT02254421 Phase 2 Presatovir;Placebo
31 Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection Completed NCT02135614 Phase 2 Presatovir;Presatovir placebo
32 Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study Completed NCT02718937 Phase 2 BTA-C585 oral capsule;Matching placebo capsules
33 Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season Completed NCT00316264 Phase 2
34 A Study to Evaluate a Single IM Dose of Motavizumab Treatment of Children With RSV (Respiratory Syncytial Virus) Illness Completed NCT00435227 Phase 2
35 RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness Completed NCT00632463 Phase 2
36 A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness Completed NCT00421304 Phase 2
37 Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults Completed NCT02266628 Phase 2
38 A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease Completed NCT00538785 Phase 2
39 Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year. Completed NCT02593071 Phase 2
40 A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection Recruiting NCT03332459 Phase 2 Lumicitabine;Placebo
41 Viral Inhibition in Children for Treatment of RSV Recruiting NCT02654171 Phase 2 AK0529;Placebo
42 An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults Recruiting NCT03334695 Phase 2 Placebo
43 A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus Recruiting NCT03379675 Phase 2 JNJ-53718678 500 mg;JNJ-53718678 80 mg;Placebo
44 RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 23 Months Recruiting NCT02927873 Phase 2 Placebo LD;Placebo MD;Placebo HD
45 A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. Active, not recruiting NCT02878330 Phase 2 MEDI8897;Placebo
46 RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults Active, not recruiting NCT02873286 Phase 2
47 Respiratory Syncytial Virus - RSV Protocol Active, not recruiting NCT01502072 Phase 2 Ribavirin;Ribavirin
48 A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Suspended NCT03333317 Phase 2 Lumicitabine;Placebo
49 Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant Terminated NCT01432080 Phase 2 Prednisone;Azithromycin;Montelukast;Symbicort
50 A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers Withdrawn NCT03191383 Phase 2 Placebo (Formulation buffer S9b)

Search NIH Clinical Center for Respiratory Syncytial Virus Infectious Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: respiratory syncytial virus infections

Genetic Tests for Respiratory Syncytial Virus Infectious Disease

Anatomical Context for Respiratory Syncytial Virus Infectious Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Respiratory Syncytial Virus Infectious Disease:

19
Upper Respiratory Tract Or

MalaCards organs/tissues related to Respiratory Syncytial Virus Infectious Disease:

41
Lung, Heart, Bone Marrow, Bone, Testes, Neutrophil, T Cells

Publications for Respiratory Syncytial Virus Infectious Disease

Articles related to Respiratory Syncytial Virus Infectious Disease:

(show top 50) (show all 156)
# Title Authors Year
1
Case report of severe myocarditis in an immunocompromised child with Respiratory Syncytial Virus infection. ( 29433478 )
2018
2
Respiratory syncytial virus infection up-regulates TLR7 expression by inducing oxidative stress via the Nrf2/ARE pathway in A549 cells. ( 29392496 )
2018
3
Thymus activity measured by T-cell receptor excision circles in patients with different severities of respiratory syncytial virus infection. ( 28056841 )
2017
4
Mechanisms and roles by which IRF-3 mediates the regulation of ORMDL3 transcription in respiratory syncytial virus infection. ( 28336364 )
2017
5
Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease. ( 28070870 )
2017
6
BRD4 Couples NF-I_B/RelA with Airway Inflammation and the IRF-RIG-I Amplification Loop in Respiratory Syncytial Virus Infection. ( 28077651 )
2017
7
Pulmonary interstitial emphysema due to respiratory syncytial virus infection. ( 27435178 )
2016
8
Respiratory Syncytial Virus Infection Triggers Epithelial HMGB1 Release as a Damage-Associated Molecular Pattern Promoting a Monocytic Inflammatory Response. ( 27535058 )
2016
9
High Frequency Jet Ventilation in Respiratory Failure Secondary to Respiratory Syncytial Virus Infection: A Case Series. ( 27626028 )
2016
10
Interleukin-4 polymorphism is associated with severity of respiratory syncytial virus infection. ( 26289664 )
2016
11
ISG15 Is Upregulated in Respiratory Syncytial Virus Infection and Reduces Virus Growth through Protein ISGylation. ( 26763998 )
2016
12
Gu-Ben-Fang-Xiao decoction attenuates sustained airway inflammation by suppressing ER stress response in a murine asthma remission model of respiratory syncytial virus infection. ( 27660012 )
2016
13
Suppression of IRG-1 Reduces Inflammatory Cell Infiltration and Lung Injury in Respiratory Syncytial Virus Infection by Reducing Production of Reactive Oxygen Species. ( 27252532 )
2016
14
Respiratory Syncytial Virus-Infected Mesenchymal Stem Cells Regulate Immunity via Interferon Beta and Indoleamine-2,3-Dioxygenase. ( 27695127 )
2016
15
Respiratory syncytial virus infection and bronchial hyperreactivity in children up to two years of age in correlation with atopy. ( 26964386 )
2016
16
Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease. ( 27628014 )
2016
17
ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. ( 26452996 )
2015
18
Genetic Polymorphisms of Toll-like Receptor 4 are Associated with Respiratory Syncytial Virus Infection in a Chinese Infant Population. ( 26642699 )
2015
19
Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells. ( 25972545 )
2015
20
Respiratory syncytial virus infection inhibits TLR4 signaling via up-regulation of miR-26b. ( 26222045 )
2015
21
CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. ( 26297201 )
2015
22
Nasopharyngeal gene expression, a novel approach to study the course of respiratory syncytial virus infection. ( 25261323 )
2015
23
Leptin Is Oversecreted by Respiratory Syncytial Virus-Infected Bronchial Epithelial Cells and Regulates Th2 and Th17 Cell Differentiation. ( 26184438 )
2015
24
Respiratory syncytial virus infection in infants with acute leukemia: a retrospective survey of the Japanese Pediatric Leukemia/Lymphoma Study Group. ( 26520649 )
2015
25
4EBP1 Is Dephosphorylated by Respiratory Syncytial Virus Infection. ( 26305094 )
2015
26
Decapping protein 1 phosphorylation modulates IL-8 expression during respiratory syncytial virus infection. ( 25796077 )
2015
27
Natural helper cells contribute to pulmonary eosinophilia by producing IL-13 via IL-33/ST2 pathway in a murine model of respiratory syncytial virus infection. ( 26044350 )
2015
28
Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection. ( 25465101 )
2015
29
Assessment of genetic associations between common single nucleotide polymorphisms in RIG-I-like receptor and IL-4 signaling genes and severe respiratory syncytial virus infection in children: a candidate gene case-control study. ( 24949794 )
2014
30
Respiratory syncytial virus infection disrupts monolayer integrity and function in cystic fibrosis airway cells. ( 24056672 )
2013
31
Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. ( 23926350 )
2013
32
Marked induction of matrix metalloproteinase-10 by respiratory syncytial virus infection in human nasal epithelial cells. ( 24009192 )
2013
33
A life-threatening respiratory syncytial virus infection: a previously healthy infant with bilateral spontaneous pneumothorax and acute respiratory distress syndrome. ( 24382538 )
2013
34
Increased hydroxymethylglutaryl coenzyme A reductase activity during respiratory syncytial virus infection mediates actin dependent inter-cellular virus transmission. ( 23994498 )
2013
35
CDK9-dependent transcriptional elongation in the innate interferon-stimulated gene response to respiratory syncytial virus infection in airway epithelial cells. ( 23596302 )
2013
36
Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. ( 24231153 )
2013
37
VLCAD deficiency in a patient who recovered from ventricular fibrillation, but died suddenly of a respiratory syncytial virus infection. ( 24330285 )
2013
38
KLF6 and iNOS regulates apoptosis during respiratory syncytial virus infection. ( 23831683 )
2013
39
Differential response of BDCA-1+ and BDCA-3+ myeloid dendritic cells to respiratory syncytial virus infection. ( 23829893 )
2013
40
Respiratory syncytial virus infection in hospitalized children older than 2 years with community-acquired pneumonia. ( 24376320 )
2013
41
Respiratory syncytial virus infection increases regulated on activation normal T cell expressed and secreted and monocyte chemotactic protein 1 levels in serum of patients with asthma and in human monocyte cultures. ( 22541401 )
2012
42
TLR2/MyD88/NF-I_B pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC inflammasome during respiratory syncytial virus infection. ( 22295065 )
2012
43
Respiratory syncytial virus infection augments NOD2 signaling in an IFN-I^-dependent manner in human primary cells. ( 22730064 )
2012
44
Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. ( 22981788 )
2012
45
Clara cell protein 10 polymorphism is not associated with severe respiratory syncytial virus infection. ( 21767304 )
2012
46
Rapid acute onset of bronchiolitis obliterans syndrome in a lung transplant recipient after respiratory syncytial virus infection. ( 22650803 )
2012
47
Afebrile seizures associated with respiratory syncytial virus infection: a situation-related seizure disorder in early infancy. ( 21342339 )
2011
48
Bimodal effects of obesity ratio on disease duration of respiratory syncytial virus infection in children. ( 21430434 )
2011
49
Effects of respiratory syncytial virus infection and major basic protein derived from eosinophils in pulmonary alveolar epithelial cells (A549). ( 20977431 )
2011
50
Innate immunity proteins and a new truncated form of SPLUNC1 in nasopharyngeal aspirates from infants with respiratory syncytial virus infection. ( 21805676 )
2011

Variations for Respiratory Syncytial Virus Infectious Disease

Expression for Respiratory Syncytial Virus Infectious Disease

LifeMap Discovery
Genes differentially expressed in tissues of Respiratory Syncytial Virus Infectious Disease patients vs. healthy controls: 35 (show all 44)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 6.10 0.000
2 OLFM4 olfactomedin 4 Blood + 5.54 0.000
3 PRTN3 proteinase 3 Blood + 5.47 0.000
4 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) Blood + 5.04 0.000
5 MMP8 matrix metallopeptidase 8 Blood + 4.32 0.000
6 MPO myeloperoxidase Blood + 4.23 0.000
7 HP haptoglobin Blood + 4.21 0.000
8 CTSG cathepsin G Blood + 4.10 0.000
9 DEFA4 defensin, alpha 4, corticostatin Blood + 3.98 0.000
10 OTOF otoferlin Blood + 3.94 0.000
11 OLFM1 olfactomedin 1 Blood - 3.93 0.000
12 RETN resistin Blood + 3.90 0.000
13 ARG1 arginase 1 Blood + 3.89 0.000
14 GPR84 G protein-coupled receptor 84 Blood + 3.88 0.000
15 NOV nephroblastoma overexpressed Blood - 3.79 0.000
16 ELANE elastase, neutrophil expressed Blood + 3.76 0.000
17 RHAG Rh-associated glycoprotein Blood + 3.73 0.000
18 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial Blood + 3.68 0.000
19 MAOA monoamine oxidase A Blood + 3.62 0.000
20 ZDHHC19 zinc finger, DHHC-type containing 19 Blood + 3.62 0.000
21 CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 Blood + 3.55 0.000
22 KCNG1 potassium channel, voltage gated modifier subfamily G, member 1 Blood - 3.48 0.000
23 HBBP1 hemoglobin, beta pseudogene 1 Blood + 3.45 0.000
24 AZU1 azurocidin 1 Blood + 3.43 0.000
25 ANXA3 annexin A3 Blood + 3.42 0.000
26 COL17A1 collagen, type XVII, alpha 1 Blood + 3.39 0.000
27 CD177 CD177 molecule Blood + 3.38 0.000
28 PRSS33 protease, serine, 33 Blood - 3.36 0.000
29 METTL7B methyltransferase like 7B Blood + 3.33 0.000
30 GPR42 G protein-coupled receptor 42 (gene/pseudogene) Blood + 3.27 0.000
31 C1QC complement component 1, q subcomponent, C chain Blood + 3.24 0.000
32 KCTD14 potassium channel tetramerization domain containing 14 Blood + 3.22 0.000
33 DEFA3 defensin, alpha 3, neutrophil-specific Blood + 3.20 0.000
34 FGF9 fibroblast growth factor 9 Blood - 3.15 0.000
35 PTGDR2 prostaglandin D2 receptor 2 Blood - 3.15 0.000
36 RSAD2 radical S-adenosyl methionine domain containing 2 Blood + 3.13 0.000
37 ADGRE4P adhesion G protein-coupled receptor E4, pseudogene Blood - 3.11 0.000
38 MMP28 matrix metallopeptidase 28 Blood - 3.09 0.000
39 XK X-linked Kx blood group Blood + 3.08 0.000
40 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa Blood + 3.04 0.000
41 KIF5C kinesin family member 5C Blood - 3.03 0.000
42 DLK1 delta-like 1 homolog (Drosophila) Blood + 3.01 0.000
43 LRRC26 leucine rich repeat containing 26 Blood - 3.01 0.000
44 LTF lactotransferrin Blood + 3.00 0.000
Search GEO for disease gene expression data for Respiratory Syncytial Virus Infectious Disease.

Pathways for Respiratory Syncytial Virus Infectious Disease

Pathways related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 CCL3 CCL5 IFNB1 IL13 IL5 IRF1
2
Show member pathways
13.16 CCL3 CCL5 IFNB1 IL13 IL5
3
Show member pathways
12.91 CCL3 CCL5 IFNB1 IL13 IL5 IRF1
4
Show member pathways
12.26 IFNB1 IL13 IL5 IRF1
5 11.66 CCL3 IFNB1 IRF1
6 11.52 IL13 IL5 IRF1
7 11.48 CCL3 IL13 IL5
8
Show member pathways
11.37 CCL3 CCL5 IL13 IL5 IRF1
9 11.23 IL13 IL5
10 11.13 IFNB1 IRF1
11 11.12 CCL3 CCL5 IL13
12 11.05 IL13 IL5
13 10.98 IL13 IRF1
14 10.93 IL13 IL5
15 10.87 CCL5 IFNB1
16 10.81 IFNB1 IL13 IL5
17 10.72 CCL3 CCL5 IL13 IL5

GO Terms for Respiratory Syncytial Virus Infectious Disease

Cellular components related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 CCL3 CCL5 IFNB1 IL13 IL5 SFTPB
2 extracellular region GO:0005576 9.17 CCL3 CCL5 IFNB1 IL13 IL5 NEU1

Biological processes related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.73 CCL3 CCL5 IL13 IL5
2 MAPK cascade GO:0000165 9.72 CCL3 CCL5 IL5
3 neutrophil chemotaxis GO:0030593 9.62 CCL3 CCL5
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 CCL5 IL13
5 type I interferon signaling pathway GO:0060337 9.61 IFNB1 IRF1
6 positive regulation of smooth muscle cell proliferation GO:0048661 9.6 CCL5 IL13
7 protein kinase B signaling GO:0043491 9.59 CCL3 CCL5
8 monocyte chemotaxis GO:0002548 9.58 CCL3 CCL5
9 positive regulation of B cell proliferation GO:0030890 9.58 IL13 IL5
10 negative regulation of viral genome replication GO:0045071 9.57 CCL5 IFNB1
11 positive chemotaxis GO:0050918 9.56 CCL3 CCL5
12 inflammatory response GO:0006954 9.56 CCL3 CCL5 IL13 IL5
13 lymphocyte chemotaxis GO:0048247 9.54 CCL3 CCL5
14 lipopolysaccharide-mediated signaling pathway GO:0031663 9.52 CCL3 CCL5
15 positive regulation of JAK-STAT cascade GO:0046427 9.51 CCL5 IL5
16 eosinophil chemotaxis GO:0048245 9.49 CCL3 CCL5
17 positive regulation of calcium ion transport GO:0051928 9.48 CCL3 CCL5
18 positive regulation of innate immune response GO:0045089 9.46 CCL5 IFNB1
19 cellular response to interferon-beta GO:0035458 9.4 IFNB1 IRF1
20 macrophage chemotaxis GO:0048246 9.37 CCL3 CCL5
21 regulation of signaling receptor activity GO:0010469 9.35 CCL3 CCL5 IFNB1 IL13 IL5
22 negative regulation by host of viral transcription GO:0043922 9.32 CCL3 CCL5
23 positive regulation of natural killer cell chemotaxis GO:2000503 9.16 CCL3 CCL5
24 cytokine-mediated signaling pathway GO:0019221 9.02 CCL3 CCL5 IFNB1 IL13 IL5

Molecular functions related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CCL3 CCL5
2 chemoattractant activity GO:0042056 9.4 CCL3 CCL5
3 CCR chemokine receptor binding GO:0048020 9.37 CCL3 CCL5
4 cytokine receptor binding GO:0005126 9.32 IFNB1 IL13
5 CCR5 chemokine receptor binding GO:0031730 9.26 CCL3 CCL5
6 phospholipase activator activity GO:0016004 9.16 CCL3 CCL5
7 cytokine activity GO:0005125 9.02 CCL3 CCL5 IFNB1 IL13 IL5
8 CCR1 chemokine receptor binding GO:0031726 8.96 CCL3 CCL5

Sources for Respiratory Syncytial Virus Infectious Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....